AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
Posted on: Friday, 6 March 2009, 17:59 CST
ASC-J9(TM) demonstrated a clinical benefit in reducing inflammatory lesions compared to placebo at certain dosages and at multiple time points during the study, though the study was not powered for statistical significance. ASC will now focus on bolstering efficacy through a new formulation and intends on forming a co-development or licensing partnership for future clinical development and commercialization. Through enhancing androgen receptor protein degradation, ASC-J9(TM) represents the first topical agent directed at modulating the effect of androgens (male hormones), through the androgen receptor, a key causative factor in the pathogenesis of acne.
ASC-J9(TM) is a small molecule with a novel mechanism of action, which selectively enhances androgen receptor degradation (ARD) to reduce androgen activity. ARD enhancers act on a key cause of acne, the androgen activation system, through reducing high levels of androgen receptor present in the sebaceous gland to lower sebum secretion, a fundamentally different approach from all other current acne treatments. ASC-J9(TM) cream is topically administered and exhibits low systemic absorption, limiting systemic side effect risks and allowing for the treatment of both males and females.
In addition to acne indication, AndroScience is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar muscular atrophy (Kennedy's Disease - a neuron motor disease caused by AR mutation) utilizing systemic based approaches.
AndroScience Corporation
SOURCE AndroScience Corporation
Source: PR Newswire
Related Articles
- Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program
- Clinical Topicals Makes Breakthrough Migraine Treatment Available Free to Soldiers
- Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results and Provides Corporate and Clinical Updates
- Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
- EntreMed Announces 2008 Corporate and Clinical Program Priorities
- Ligand Announces Positive Preclinical Data on Selective Androgen Receptor Modulator LGD-3303
- HomePlug(R) Powerline Alliance Welcomes New Contributor Members Huawei Technologies and Corporate Systems Engineering
- FermaVir Announces FDA Response to Its Pre-IND Submission for Initial Bioavailability Studies in Human Clinical Trials of FV-100; Response Enables Company to Plan Clinical Development Program for Novel Antiviral Drug Candidate
- Met-Pro Corporation's Systems Division Receives Equipment Order Totaling Approximately $900,000
- Study Demonstrates That BenzaClin(R) Topical Gel (Clindamycin 1% - Benzoyl Peroxide 5% Gel) Provided a Numerically Greater Reduction in Acne Lesions Than Tretinoin 0.025% Gel Plus Clindamycin 1% Gel
 |
 |
User Comments (0)
RSS Feeds